Kevin Patrick Danahy - Apr 29, 2023 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role
Chief Executive Officer
Signature
/s/ Kenneth B. Stratton, as Attorney-in-Fact
Stock symbol
PLSE
Transactions as of
Apr 29, 2023
Transactions value $
$0
Form type
4
Date filed
5/2/2023, 09:45 PM
Previous filing
Oct 3, 2022
Next filing
Jul 14, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLSE Stock Option (right to buy) Award +500K 500K Apr 29, 2023 Common Stock 500K $6.44 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on April 29, 2023 under the Issuer's 2017 Equity Incentive Plan. The shares subject to the option are subject to four tranches of performance-based vesting criteria tied to Issuer's market capitalization, with no vesting until the Issuer's market capitalization exceeds $1 billion, in all cases, subject to the Reporting Person's continued service through each vesting milestone.
F2 Not applicable.